HIV Treatment and Prevention Agents Related Topics 
Express Pharma
DECEMBER 14, 2023
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body. It is indicated for the treatment of HIV-1 infection in adult patients. It is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older.
Pharmacy Friday Pearls
MARCH 4, 2022
18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
RX Note
JUNE 21, 2023
Introduction HIV (Human immunodeficiency virus) is an enveloped, single-stranded RNA virus that was recognized as the causative agent of AIDS (acquired immune deficiency syndrome). If HIV is left untreated, the virus will cause progressive weakening of the immune system, a process which occurs at different rates in different people.
pharmaphorum
JANUARY 5, 2022
The next phase of the Covid-19 – from vaccines to treatments. New COVID-19 treatments will also be available in 2022, but they are not a panacea. Pfizer reported in early December that Paxlovid, now also approved in US, Europe and UK, retained 89% efficacy in preventing hospitalisation and death from an earlier readout.
RX Note
JULY 3, 2023
. ° Nil © Complete ABG Arterial blood gases abx Antibiotics ACE Angiotensin converting enzyme ACS Acute coronary syndrome ADHD Attention deficit hyperactivity disorder ADME Absorption, distribution, metabolism or excretion ADR Adverse drug reaction AEBA Acute exacerbation of bronchial asthma AF Atrial fibrillation AGE Acute gastroenteritis AIDS Acquired (..)
PharmaShots
APRIL 25, 2023
This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.
Expert insights. Personalized for you.
105 
Let's personalize your content